Clinical trial Recruiting at 12 sites Phase 3 Interventional Ages 6 to 11

Delay nearsightedness in high-risk children with nightly low-dose eye drops

Official title: Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial

Run by Ohio State University · NCT07567040 · Data updated 2026-11-12

This will test whether giving children ages 6–11 nightly 0.05% atropine eye drops delays the start of nearsightedness compared with nightly placebo drops.

Quick facts

PhasePhase 3
Study typeInterventional
Ages6 Years to 11 Years
SexAll
Enrollment664 (estimated)
SponsorOhio State University
Academic / other
Locations13 sites (Birmingham, Alabama and 12 other locations)
StatusRecruiting
StartedMay 27, 2026
Main results expectedMay 15, 2028
Study endsMay 15, 2028
Registry record updatedSeptember 21, 2026
Trial IDNCT07567040 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 6–11 judged to be at high risk for myopia onset who meet the study's refractive and ocular health criteria and can adhere to nightly drops and regular visits.

Probably not a fit

Children who already have at least −0.75 D myopia in either eye, who have strabismus, a known allergy to atropine, systemic issues affecting accommodation, or who cannot commit to nightly dosing and follow-up are unlikely to benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The DONUT trial is a multicenter, randomized, placebo-controlled Phase 3 trial enrolling 606 children aged 6–11 who are at high risk for developing myopia. Participants are randomized to nightly 0.05% atropine eye drops or matching placebo and are followed every six months for at least two years to measure refractive error and axial length. The primary outcome is the two-year cumulative incidence of myopia; a key secondary outcome is the rate of axial elongation. A short run-in period with unit-dose artificial tears confirms participants can reliably administer nightly drops before randomization.

Why it matters

Potential benefit: If successful, nightly low‑dose atropine could reduce how many children develop myopia and slow the eye growth that leads to worsening vision.

How similar studies have gone: Previous trials have shown low‑dose atropine can slow myopia progression, but using 0.05% atropine specifically to delay the initial onset of myopia is less well tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Refractive Error (cycloplegic autorefraction, spherical equivalent, at least one eye, inclusive) 6 years: -0.74 D to +0.75 D 7 and 8 years: -0.74 D to +0.50 D 9 and 10 years: -0.74 D to +0.25 D 11 years: -0.74 D to plano
* Neither eye has -0.75 D or more myopia, spherical component
* Anisometropia: Less than 1.50 D difference between OD and OS, cycloplegic autorefraction, spherical equivalent
* Astigmatism: Less than 1.50 DC in both eyes by cycloplegic autorefraction
* Successfully complete run-in period: take at least 90% of unit dose artificial tears for 2 to 4 weeks (# of unit-dose vials used divided by # nights since baseline visit must equal 0.90 or greater)

Exclusion Criteria:

* If Visit 2 (randomization visit) is not completed within 4 weeks of the baseline, eligibility visit.
* Presence of strabismus (intermittent or constant) based on unilateral cover test at distance and near
* Known allergy to atropine
* Systemic issues that may affect accommodation or convergence (e.g., multiple sclerosis, myasthenia gravis, Graves ophthalmopathy, diabetes mellitus, Parkinson's disease, Down syndrome, etc.)
* Ocular disease (e.g., congenital glaucoma, retinal disease, nystagmus, amblyopia, etc.)
* Ocular surgery (e.g., cataracts, strabismus)
* Any previous myopia prevention/control therapy (e.g., atropine, soft contact lenses, orthokeratology, myopia control spectacles, etc.) for more than one month
* Pregnancy by self-report

Where it's running

  • University of Alabama School of Optometry
    Birmingham, Alabama, United States
    Recruiting
  • University of California, Berkeley, School of Optometry
    Berkeley, California, United States
    Recruiting
  • Southern California College of Optometry at Marshall B. Ketchum University
    Fullerton, California, United States
    Recruiting
  • Stanford University
    Palo Alto, California, United States
    Recruiting
  • Illinois College of Optometry
    Chicago, Illinois, United States
    Recruiting
  • Indiana University
    Bloomington, Indiana, United States
    Recruiting
Show 7 more locations
  • New England College of Optometry
    Boston, Massachusetts, United States
    Recruiting
  • State University of New York College of Optometry
    New York, New York, United States
    Recruiting
  • The Ohio State University College of Optometry
    Columbus, Ohio, United States
    Recruiting
  • Pennsylvania College of Optometry at Drexel University
    Elkins Park, Pennsylvania, United States
    Recruiting
  • Southern College of Optometry
    Memphis, Tennessee, United States
    Recruiting
  • University of Houston College of Optometry
    Houston, Texas, United States
    Recruiting
  • Case Western Reserve Department of Ophthalmology
    Cleveland, Ohio, United States
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.